Angiotensin Receptors and Age Related Mitochondrial Decline in HIV Patients

Not Applicable

Terminated

Conditions: HIV
Aging
Sarcopenia
Angiotensin Receptor Antagonists

Interventions: Other: Placebo
Drug: valsartan

Registration Number: NCT02606279

Lead Sponsor: Wake Forest University Health Sciences

Brief Summary: This study is designed to evaluate specific factors in mitochondria that may precipitate premature aging and physical weakness in HIV patients. Angiotensin receptors 1 and 2 (AT1R and AT2R) are found in virtually every cell type. This study will evaluate how the relationships among these receptors in immune and skeletal muscle cells change with HIV, and how these changes might trigger mitochondrial dysfunction, declines in muscle strength, and cellular decline in people living with HIV.

Detailed Description: HIV related premature cellular aging and declines in mitochondrial function are closely linked. Dysfunctional mitochondria generate higher levels of reactive oxygen species (ROS) and provide less ATP supply cellular energy. Impaired turnover of damaged mitochondria leads to gradual but progressive decline in energy metabolism, increases in muscle fibrosis and clinically apparent weakness. The Renin Angiotensin System (RAS) is a central hormonal system that contributes to mitochondrial dysfunction and impacts both lifespan and function across multiple organ systems. Deletion of the angiotensin type 1 receptor (AT1R) results in a 25-30% extension of lifespan in mouse models, partly through increasing mitochondrial numbers. Blocking of AT1R reduces a number of age-related morbidities in mice, and in human studies. A plethora of data implicates RAS modulation in marked effects on fitness, frailty and beneficial responses to exercise in older adults. Despite this, there are virtually no data examining RAS biology in HIV+ vs. age-matched HIVsubjects, no data of RAS in relation to key HIV-specific variables (duration of HIV, treatment history, immune markers), and no data examining the effects of blocking AT1R on physical function in HIV infected subjects. In this study, we will examine the RAS and its contribution to premature mitochondrial failure in HIV patients. We will begin to fill this void by enrolling 40 HIV+ subjects in a randomized, double-blinded, placebo controlled pilot study of treatment with AT1R blocker to determine the feasibility of a larger trial, estimate effect size, assess the correlation of angiotensin receptor (AR) expression in peripheral blood cells and muscle cells, and the association of AR expression with physical function measures and immunity.

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 1

Inclusion Criteria

able to provide informed consent
able to attend an extended (~4 hour) Clinical Research Visit
documented HIV seropositivity
on a stable anti-retroviral therapy (ART) regimen for at least 12 months
HIV plasma viral load < 50 copies/ml for at least 6 months
Systolic blood pressure >110

Exclusion Criteria

creatinine > 1.5 ULN (or creatinine clearance < 60 ml/min)
anti-hypertensive therapy with ACE-I or AT1R-blockers
inability to perform functional measures (e.g. non-ambulatory without assistance, requires a prosthesis)
recent (within 30 days) acute illness requiring medical therapy or hospitalization
immunosuppressive agents (e.g. > 20 mg/d x 2 or more weeks of prednisone or equivalent, chemotherapy) in the last 6 months
cancer requiring treatment w/in 3 yrs (except for non-melanoma skin cancer)
blood thinning medications such as Coumadin or Plavix or a bleeding disorder such as hemophilia that could cause complications during muscle biopsies
pregnancy (will provide urine test for females of child bearing potential)
regular use of non-steroidal anti-inflammatory drugs or other immune modulating agents.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo control	Placebo	20 HIV-infected participants will be randomized into a blinded arm where they will receive 24 weeks of placebo therapy. During this time, they will undergo the same study procedures as the intervention arm.
Valsartan	valsartan	20 HIV-infected participants will be randomized into a blinded arm where they receive 24 weeks of valsartan therapy. For those subjects randomized to the valsartan group, they will receive valsartan 40 mg by mouth daily for 2 weeks, then increase to 80 mg by mouth daily for the remaining 22 weeks. During this time, they will undergo the same study procedures as the placebo arm.

Primary Outcome Measures

Name	Time	Method
Change From Baseline in 400m Walk	3, 6, and 9 months post-enrollment	Measured by time to finish 400 meter walk
Change From Baseline in Grip Strength	3, 6, and 9 months post-enrollment	Measured by dynamometer measurement of grip strength
Change From Baseline in Quantity of AT1R and AT2R on Monocytes	3, 6, and 9 months post-enrollment	Measured by using qPCR and western blot. (Units are arbitrary units)